Phase 3CompletedAge-related condition
Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS) (N30-003)
A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
- Sponsor
- Noven Therapeutics (Industry)
- Enrollment
- 614 enrolled
- Conditions
- Postmenopausal Symptoms
- Interventions
- Brisdelle (paroxetine mesylate); Placebo capsules
- Ages
- adults, older adults
- Registry
- NCT01361308
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to assess the safety \& efficacy of Brisdelle (paroxetine mesylate) Capsules 7.5 mg for treatment of vasomotor symptoms (VMS) associated with menopause.
Primary outcomes
- Mean Change in Frequency of Moderate to Severe VMS From Baseline at Week 4 and Week 12.
- Mean Change From Baseline in Hot Flash Severity at Week 4 and Week 12
History
Last registry update
Results first posted
Study completion
Primary completion
Registered
Started